Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Papillary Thyroid Cancer: early-phase trial registry
4 of 7 indexed Papillary Thyroid Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Papillary Thyroid Cancer: 7 US clinical trials tracked, 4 recruiting.
Papillary Thyroid Cancer is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 1 of these trials.
Enrollment posture brief
Registry condition papillary-thyroid-cancer
OPEN 4 | RECR 57% | LATE 0 | EARLY 3 | RANK #2497 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)
Papillary Thyroid Cancer lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Papillary Thyroid Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Papillary Thyroid Cancer is recruiting above its size-band peers.
4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Papillary Thyroid Cancer trials is spread across many organizations.
Eli Lilly and Company accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Papillary Thyroid Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.
-
Papillary Thyroid Cancer splits between interventional and observational designs.
4 interventional and 3 observational studies make up this index (57.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
Studies on Tumors of the Thyroid
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00001160
Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers
M.D. Anderson Cancer Center
NCT07140757
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Children's Hospital of Philadelphia
NCT05024929
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
NCT05668962
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Eli Lilly and Company
NCT03899792
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Memorial Sloan Kettering Cancer Center
NCT04544111
Radiofrequency Ablation of Papillary Thyroid Microcarcinoma
Johns Hopkins University
NCT05132205
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Papillary Thyroid Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Papillary Thyroid Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Papillary Thyroid Cancer page
7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Papillary Thyroid Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Papillary Thyroid Cancer trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Papillary Thyroid Cancer condition card totals 7 registered trials; most-linked intervention Selpercatinib; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.